Exchange: NYSE·Updated 07:34 PM EST

ZTS News

News
all
press releases
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript...
SeekingAlpha
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript...
SeekingAlpha
More News
ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
Zacks
Zoetis Inc. (NYSE: ZTS) today announced that the United States Department of Agriculture (USDA) has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. Cytopoint Plus is the first and only USDA-licensed next-generation monoclonal antibody (mAb) that provides 75 days of...
Business Wire
Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast...
Business Wire
Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
Zacks
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Zoetis Inc (Symbol: ZTS) has taken over the #296 spot from ResMed Inc. (Symbol: RMD), according to The Online Investor. Market capitalization is an important data poi...
Nasdaq News: Markets
Key PointsZoetis's organic operational revenue fell 1% in the third quarter...
Nasdaq News: Markets
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Zoetis beats Q3 earnings and revenue estimates, lifts full-year 2026 guidance, and balances pet care affordability pressures with steady livestock gains.read more...
Benzinga
Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.
Zacks

Advertisement|Remove ads.